Bridgeway Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-186,254
| Closed | -$115K | – | 1459 |
|
|
2018
Q4 | $115K | Hold |
186,254
| – | – | ﹤0.01% | 1288 |
|
|
2018
Q3 | $242K | Hold |
186,254
| – | – | ﹤0.01% | 1288 |
|
|
2018
Q2 | $251K | Buy |
186,254
+34,400
| +23% | +$52.7K | ﹤0.01% | 1283 |
|
|
2018
Q1 | $220K | Buy |
151,854
+3,800
| +3% | +$7.94K | ﹤0.01% | 1260 |
|
|
2017
Q4 | $333K | Hold |
148,054
| – | – | ﹤0.01% | 1191 |
|
|
2017
Q3 | $503K | Hold |
148,054
| – | – | 0.01% | 1091 |
|
|
2017
Q2 | $526K | Hold |
148,054
| – | – | 0.01% | 1079 |
|
|
2017
Q1 | $503K | Hold |
148,054
| – | – | 0.01% | 1074 |
|
|
2016
Q4 | $681K | Hold |
148,054
| – | – | 0.01% | 954 |
|
|
2016
Q3 | $628K | Hold |
148,054
| – | – | 0.01% | 979 |
|
|
2016
Q2 | $355K | Hold |
148,054
| – | – | 0.01% | 1179 |
|
|
2016
Q1 | $696K | Hold |
148,054
| – | – | 0.01% | 918 |
|
|
2015
Q4 | $582K | Buy |
148,054
+73,750
| +99% | +$340K | 0.01% | 995 |
|
|
2015
Q3 | $288K | Buy |
74,304
+60,942
| +456% | +$280K | 0.01% | 1229 |
|
|
2015
Q2 | $61K | Hold |
13,362
| – | – | ﹤0.01% | 1458 |
|
|
2015
Q1 | $90K | Hold |
13,362
| – | – | ﹤0.01% | 1424 |
|
|
2014
Q4 | $43K | Buy |
+13,362
| New | +$53.8K | ﹤0.01% | 1439 |
|
Bridgeway Capital Management's AST Position: Q1 2019 in Review
Bridgeway Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 186,254 shares — an estimated $115K sold.
Bridgeway Capital Management first reported a position in AST in Q4 2014 and held it in 17 quarters. The position peaked at $696K in Q1 2016. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Bridgeway Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Bridgeway Capital Management sold 186,254 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $115K.
- Bridgeway Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 17 quarters.
- Bridgeway Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $696K in Q1 2016.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Bridgeway Capital Management's 13F filing for Q1 2019, filed 15 May 2019.